- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
International Journal of Medicinal Chemistry
Volume 2011 (2011), Article ID 539245, 7 pages
Evaluation of a Set of C9 N-acyl Neu5Ac2en Mimetics as Viral Sialidase Selective Inhibitors
1Department of Applied Bioorganic Chemistry, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan
2Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, USA
3Faculty of Medicine, Thammasat University (Rangsit Campus), Pathumthani, Thailand
4Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University, Aichi, Japan
5Cancer Glycosylation Research, Institute of Molecular Biomembrane and Glycobiology, Tohoku Pharmaceutical University, Sendai, Japan
6Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University, Japan
Received 2 October 2010; Revised 16 November 2010; Accepted 16 November 2010
Academic Editor: Giulio Rastelli
Copyright © 2011 Sadagopan Magesh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- World Health Organization, http://www.who.int/csr/disease/avian_influenza/en/.
- A. S. Monto, “Epidemiology of influenza,” Vaccine, vol. 26, no. 4, pp. D45–D48, 2008.
- N. J. Cox and K. Subbarao, “Global epidemiology of influenza: past and present,” Annual Review of Medicine, vol. 51, pp. 407–421, 2000.
- E. De Clercq, “Antiviral agents active against influenza A viruses,” Nature Reviews Drug Discovery, vol. 5, no. 12, pp. 1015–1025, 2006.
- M. C. Zambon, “Epidemiology and pathogenesis of influenza,” Journal of Antimicrobial Chemotherapy, vol. 44, pp. 3–9, 1999.
- D. A. Steinhauer and J. J. Skehel, “Genetics of influenza viruses,” Annual Review of Genetics, vol. 36, pp. 305–332, 2002.
- C. F. Basler, “Influenza viruses: basic biology and potential drug targets,” Infectious Disorders-Drug Targets, vol. 7, no. 4, pp. 282–293, 2007.
- Y. Suzuki, “Sialobiology of influenza molecular mechanism of host range variation of influenza viruses,” Biological and Pharmaceutical Bulletin, vol. 28, no. 3, pp. 399–408, 2005.
- J. Skehel, “An overview of influenza haemagglutinin and neuraminidase,” Biologicals, vol. 37, no. 3, pp. 177–178, 2009.
- R. J. Russell, L. F. Haire, D. J. Stevens et al., “The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design,” Nature, vol. 443, no. 7107, pp. 45–49, 2006.
- P. J. Collins, L. F. Haire, Y. P. Lin et al., “Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants,” Nature, vol. 453, no. 7199, pp. 1258–1261, 2008.
- A. Moscona, “Neuraminidase inhibitors for influenza,” The New England Journal of Medicine, vol. 353, no. 13, pp. 1363–1373, 2005.
- A. Moscona, “Global transmission of oseltamivir-resistant influenza,” The New England Journal of Medicine, vol. 360, no. 10, pp. 953–956, 2009.
- M. L. Mihajlovic and P. M. Mitrasinovic, “Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV),” Biophysical Chemistry, vol. 136, no. 2-3, pp. 152–158, 2008.
- M. L. Mihajlović and P. M. Mitrašinović, “Some novel insights into the binding of oseltamivir and zanamivir to H5N1 and N9 influenza virus neuraminidases: a homology modeling and flexible docking study,” Journal of the Serbian Chemical Society, vol. 74, no. 1, pp. 1–13, 2009.
- M. L. Mihajlovic and P. M. Mitrasinovic, “Applications of the ArgusLab4/AScore protocol in the structure-based binding affinity prediction of various inhibitors of group-1 and group-2 influenza virus neuraminidases (NAs),” Molecular Simulation, vol. 35, no. 4, pp. 311–324, 2009.
- M. Z. Wang, C. Y. Tai, and D. B. Mendel, “Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 12, pp. 3809–3816, 2002.
- Q. S. Du, S. Q. Wang, and K. C. Chou, “Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus,” Biochemical and Biophysical Research Communications, vol. 362, no. 2, pp. 525–531, 2007.
- P. M. Mitrasinovic, “On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA),” Biophysical Chemistry, vol. 140, no. 1-3, pp. 35–38, 2009.
- P. M. Mitrasinovic, “Advances in the structure-based design of the influenza a neuraminidase inhibitors,” Current Drug Targets, vol. 11, no. 3, pp. 315–326, 2010.
- M. N. Matrosovich, T. Y. Matrosovich, T. Gray, N. A. Roberts, and H. D. Klenk, “Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium,” Journal of Virology, vol. 78, no. 22, pp. 12665–12667, 2004.
- M. von Itzstein, “The war against influenza: discovery and development of sialidase inhibitors,” Nature Reviews Drug Discovery, vol. 6, no. 12, pp. 967–974, 2007.
- P. Meindl and H. Tuppy, “2-deoxy-2,3-dehydrosialic acids. II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2,3-dehydro-N-acylneuraminic acids,” Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, vol. 350, no. 9, pp. 1088–1092, 1969.
- M. von Itzstein, J. C. Dyason, S. W. Oliver et al., “A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs,” Journal of Medicinal Chemistry, vol. 39, no. 2, pp. 388–391, 1996.
- W. Lew, X. Chen, and C. U. Kim, “Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor,” Current Medicinal Chemistry, vol. 7, no. 6, pp. 663–672, 2000.
- E. A. Govorkova, I. A. Leneva, O. G. Goloubeva, K. Bush, and R. G. Webster, “Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 10, pp. 2723–2732, 2001.
- N. A. Roberts and E. A. Govorkova, “The activity of neuraminidase inhibitor oseltamivir against all subtypes of influenza viruses,” in Global View of the Fight against Influenza, P. M. Mitrasinovic, Ed., pp. 93–118, Nova Science Publishers, New York, NY, USA, 2009.
- R. Hama, “Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships,” International Journal of Risk and Safety in Medicine, vol. 20, no. 1-2, pp. 5–36, 2008.
- USA Today, FDA Adds 'Abnormal Behavior' Precaution to Tamiflu Label, Associated Press, 2006.
- K. Hata, K. Koseki, K. Yamaguchi et al., “Limited inhibitory effects of oseltamivir and zanamivir on human sialidases,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 10, pp. 3484–3491, 2008.
- C. Y. Li, Q. Yu, Z. Q. Ye et al., “A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir,” Cell Research, vol. 17, no. 4, pp. 357–362, 2007.
- T. Miyagi, K. Kato, S. Ueno, and T. Wada, “Aberrant expression of sialidase in cancer,” Trends in Glycoscience and Glycotechnology, vol. 16, no. 92, pp. 371–381, 2004.
- R. Schauer, “Chemistry, metabolism, and biological functions of sialic acids,” Advances in Carbohydrate Chemistry and Biochemistry, vol. 40, pp. 131–234, 1982.
- K. E. Achyuthan and A. M. Achyuthan, “Comparative enzymology, biochemistry and pathophysiology of human exo-α-sialidases (neuraminidases),” Comparative Biochemistry and Physiology B, vol. 129, no. 1, pp. 29–64, 2001.
- L. M. G. Chavas, C. Tringali, P. Fusi et al., “Crystal structure of the human cytosolic sialidase Neu2: evidence for the dynamic nature of substrate recognition,” Journal of Biological Chemistry, vol. 280, no. 1, pp. 469–475, 2005.
- S. Magesh, T. Suzuki, T. Miyagi, H. Ishida, and M. Kiso, “Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: hints for the design of selective NEU3 inhibitors,” Journal of Molecular Graphics and Modelling, vol. 25, no. 2, pp. 196–207, 2006.
- T. Wang and R. C. Wade, “Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes,” Journal of Medicinal Chemistry, vol. 44, no. 6, pp. 961–971, 2001.
- A. R. Ortiz, M. T. Pisabarro, F. Gago, and R. C. Wade, “Prediction of drug binding affinities by comparative binding energy analysis,” Journal of Medicinal Chemistry, vol. 38, no. 14, pp. 2681–2691, 1995.
- S. Magesh, S. Moriya, T. Suzuki, T. Miyagi, H. Ishida, and M. Kiso, “Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: selective inhibitors of lysosomal sialidase (NEU1),” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 2, pp. 532–537, 2008.
- X. Xu, X. Zhu, R. A. Dwek, J. Stevens, and I. A. Wilson, “Structural characterization of the 1918 influenza virus H1N1 neuraminidase,” Journal of Virology, vol. 82, no. 21, pp. 10493–10501, 2008.
- DS Modeling v1.50, Accelrys, San Diego, Calif, USA.
- A. Bairoch and R. Apweiler, “The SWISS-PROT protein sequence database: its relevance to human molecular medical research,” Journal of Molecular Medicine, vol. 75, no. 5, pp. 312–316, 1997.
- J. D. Thompson, D. G. Higgins, and T. J. Gibson, “CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice,” Nucleic Acids Research, vol. 22, no. 22, pp. 4673–4680, 1994.